Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-ZIKV Envelope protein E Antibody (Z23)

Catalog #:   VVV31401 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1-kappa
Applications: ELISA, Neutralization
Accession: A0A1B0XTC8
Overview

Catalog No.

VVV31401

Species reactivity

Zika virus (ZIKV)

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Genome polyprotein, Envelope protein E

Concentration

2.4 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

A0A1B0XTC8

Applications

ELISA, Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Z23

Data Image
References

Genome-Wide Analysis of Stable RNA Secondary Structures across Multiple Organisms Using Chemical Probing Data: Insights into Short Structural Motifs and RNA-Targeting Therapeutics., PMID:40131856

Identification of B-cell epitopes of Indian Zika virus strains using immunoinformatics., PMID:40083545

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice., PMID:39588106

Genome-Wide Identification of Stable RNA Secondary Structures Across Multiple Organisms Using Chemical Probing Data: Insights into Short Structural Motifs and RNA-Targeting Therapeutics., PMID:39416040

The ApoA1-mimetic peptide 4F blocks flavivirus NS1-triggered endothelial dysfunction and protects against lethal dengue virus challenge., PMID:39260777

Lipid droplets in Zika neuroinfection: Potential targets for intervention?, PMID:37820117

Development of Zika Virus Mini-Replicon Based Single-Round Infectious Particles as Gene Delivery Vehicles., PMID:37632104

Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement., PMID:37316861

In Vitro and In Vivo Models for Drug Transport Across the Blood-Testis Barrier., PMID:37258305

The Anti-Dengue Virus Peptide DV2 Inhibits Zika Virus Both In Vitro and In Vivo., PMID:37112820

Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection., PMID:37112665

Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells., PMID:37006270

Secondary metabolites as potential drug candidates against Zika virus, an emerging looming human threat: Current landscape, molecular mechanism and challenges ahead., PMID:36958171

Metabolic reprogramming and lipid droplets are involved in Zika virus replication in neural cells., PMID:36882750

Identification of desoxyrhapontigenin as a novel antiviral agent against congenital Zika virus infection., PMID:36646387

Small-Molecule Inhibitor of Flaviviral NS3-NS5 Interaction with Broad-Spectrum Activity and Efficacy In Vivo., PMID:36622141

Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein., PMID:36377874

Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases., PMID:36266654

Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model., PMID:36169338

Zika virus causes placental pyroptosis and associated adverse fetal outcomes by activating GSDME., PMID:35972780

Efficient Gene Transfer to Kidney Using a Lentiviral Vector Pseudotyped with Zika Virus Envelope Glycoprotein., PMID:35904396

Reporter Flaviviruses as Tools to Demonstrate Homologous and Heterologous Superinfection Exclusion., PMID:35891480

Sulfated β-glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis., PMID:35533778

A single nonsynonymous mutation on ZIKV E protein-coding sequences leads to markedly increased neurovirulence in vivo., PMID:35234632

Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo., PMID:35231399

Structurally Conserved Domains between Flavivirus and Alphavirus Fusion Glycoproteins Contribute to Replication and Infectious-Virion Production., PMID:34757841

Yellow fever vaccine protects mice against Zika virus infection., PMID:34735450

Robust Plasma Cell Response to Skin-Inoculated Dengue Virus in Mice., PMID:33997054

Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice., PMID:33753816

Multivalent DNA Vaccines as A Strategy to Combat Multiple Concurrent Epidemics: Mosquito-Borne and Hemorrhagic Fever Viruses., PMID:33673603

Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection., PMID:33421988

Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy., PMID:33077712

Potential for Virus Endogenization in Humans through Testicular Germ Cell Infection: the Case of HIV., PMID:32999017

Avian anti-NS1 IgY antibodies neutralize dengue virus infection and protect against lethal dengue virus challenge., PMID:32979401

NS1-based DNA vaccination confers mouse protective immunity against ZIKV challenge., PMID:32882433

Enhanced effect of modified Zika virus E antigen on the immunogenicity of DNA vaccine., PMID:32818729

Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics., PMID:32747832

Envelope protein ubiquitination drives entry and pathogenesis of Zika virus., PMID:32641828

Zika virus induces oxidative stress and decreases antioxidant enzyme activities in vitro and in vivo., PMID:32622852

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells., PMID:32523582

Antiviral Activity of Compound L3 against Dengue and Zika Viruses In Vitro and In Vivo., PMID:32517029

Reverse engineering synthetic antiviral amyloids., PMID:32504029

Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines., PMID:32472093

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement., PMID:32305868

Anti-inflammatory Compound Shows Therapeutic Safety and Efficacy against Flavivirus Infection., PMID:31636070

Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization., PMID:31367259

Zika virus differentially infects human neural progenitor cells according to their state of differentiation and dysregulates neurogenesis through the Notch pathway., PMID:31282298

Zika Virus Infects Trabecular Meshwork and Causes Trabeculitis and Glaucomatous Pathology in Mouse Eyes., PMID:31068433

In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus., PMID:30962164

Infectivity of Zika virus on primary cells support tree shrew as animal model., PMID:30866776

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-ZIKV Envelope protein E Antibody (Z23) [VVV31401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only